has been cited by the following article(s):
|
[1]
|
Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort
Open Forum Infectious Diseases,
2025
DOI:10.1093/ofid/ofaf177
|
|
|
|
|
[2]
|
Global “expiration” of abacavir in adults with HIV: a rapid review of safety and efficacy concerns challenging its role in modern ART
Therapeutic Advances in Infectious Disease,
2025
DOI:10.1177/20499361251351801
|
|
|
|
|
[3]
|
Future Opportunities and Tools for Emerging Challenges for HIV/AIDS Control [Working Title]
Infectious Diseases,
2022
DOI:10.5772/intechopen.105731
|
|
|
|
|
[4]
|
Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus‐associated cardiovascular risk
British Journal of Pharmacology,
2019
DOI:10.1111/bph.14589
|
|
|
|
|
[5]
|
Effect of aspirin treatment on abacavir-associated platelet hyperreactivity in HIV-infected patients
International Journal of Cardiology,
2018
DOI:10.1016/j.ijcard.2018.04.052
|
|
|
|
|
[6]
|
Discrepant coagulation profile in HIV infection
AIDS,
2013
DOI:10.1097/01.aids.0000432462.21723.ed
|
|
|
|